verapamil has been researched along with No-Reflow Phenomenon in 16 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to investigate the effects of verapamil and adenosine in an adjunct to intravenous tirofiban on management and prognosis of no-reflow phenomenon during primary percutaneous coronary intervention (PPCI) and to compare their efficacies on reversing of no-reflow phenomenon and short and midterm survival." | 9.19 | Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. ( Arif Yalcin, A; Biyik, I; Celik, O; Erturk, M; Faruk Akturk, I; Murat Caglar, I; Oner, E; Sarikamis, C; Turhan Caglar, N; Uzun, F, 2014) |
| "We found no evidence that adenosine and verapamil as treatments for no-reflow during PPCI can reduce all-cause mortality, non-fatal myocardial infarction or the incidence of angiographic no-reflow (TIMI flow grade < 3 and MBG 0 to1), but there was some evidence of increased adverse events." | 8.89 | Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. ( Aung Naing, K; Li, L; Su, Q; Wu, T, 2013) |
| " Randomized trials comparing the efficacy and safety of intracoronary verapamil infusion vs control in patients with acute coronary syndrome (ACS) were included." | 8.89 | Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Li, L; Liu, Y; Su, Q, 2013) |
| "The present study evaluated the efficacy of intracoronary administration of verapamil to attenuate the no-reflow phenomenon following the primary percutaneous coronary intervention (PCI) in patients with the ST-segment elevation acute myocardial infarction (STEMI)." | 7.79 | Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. ( Fu, Q; Huang, YJ; Jiang, SZ; Lu, W; Wang, HB; Wang, LG; Wang, YJ; Wu, Q, 2013) |
| " In carefully selected subgroup of SVG lesions without visible macrothrombus, a strategy of prophylactic intra-graft administration of abciximab and verapamil, combined with direct stenting of the graft lesion without pre-dilatation, can be safely accomplished without any significant risk of slow-flow/no-reflow phenomenon." | 6.77 | Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus. ( Bhambi, BK; Lardizabal, JA; Sandhu, R; Sharma, S; Singh, S, 2012) |
| "Adenosine as treatment for no-reflow during PPCI could reduce angiographic no-reflow (TIMI flow grade < 3) but was found to increase adverse events." | 6.52 | Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. ( Li, L; Nyi, TS; Su, Q, 2015) |
| "We investigated whether local injection of adrenaline ± verapamil in the distal coronary bed is more effective than their intracoronary (IC) injection through the guiding catheter in the treatment of no-reflow phenomenon following percutaneous coronary intervention (PCI)." | 5.22 | Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study. ( Abu Arab, T; El Etriby, A; Rafik, R, 2016) |
| "We aimed to investigate the effects of verapamil and adenosine in an adjunct to intravenous tirofiban on management and prognosis of no-reflow phenomenon during primary percutaneous coronary intervention (PPCI) and to compare their efficacies on reversing of no-reflow phenomenon and short and midterm survival." | 5.19 | Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. ( Arif Yalcin, A; Biyik, I; Celik, O; Erturk, M; Faruk Akturk, I; Murat Caglar, I; Oner, E; Sarikamis, C; Turhan Caglar, N; Uzun, F, 2014) |
| "No previous study has assessed the possible role of dipyridamole for treatment of no-reflow during acute myocardial infarction (AMI)." | 5.14 | Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. ( Arrivi, A; Greco, C; Mangieri, E; Pasceri, V; Pelliccia, F; Placanica, A; Tanzilli, G, 2010) |
| "We found no evidence that adenosine and verapamil as treatments for no-reflow during PPCI can reduce all-cause mortality, non-fatal myocardial infarction or the incidence of angiographic no-reflow (TIMI flow grade < 3 and MBG 0 to1), but there was some evidence of increased adverse events." | 4.89 | Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. ( Aung Naing, K; Li, L; Su, Q; Wu, T, 2013) |
| " Randomized trials comparing the efficacy and safety of intracoronary verapamil infusion vs control in patients with acute coronary syndrome (ACS) were included." | 4.89 | Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Li, L; Liu, Y; Su, Q, 2013) |
| "The present study evaluated the efficacy of intracoronary administration of verapamil to attenuate the no-reflow phenomenon following the primary percutaneous coronary intervention (PCI) in patients with the ST-segment elevation acute myocardial infarction (STEMI)." | 3.79 | Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. ( Fu, Q; Huang, YJ; Jiang, SZ; Lu, W; Wang, HB; Wang, LG; Wang, YJ; Wu, Q, 2013) |
| " In carefully selected subgroup of SVG lesions without visible macrothrombus, a strategy of prophylactic intra-graft administration of abciximab and verapamil, combined with direct stenting of the graft lesion without pre-dilatation, can be safely accomplished without any significant risk of slow-flow/no-reflow phenomenon." | 2.77 | Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus. ( Bhambi, BK; Lardizabal, JA; Sandhu, R; Sharma, S; Singh, S, 2012) |
| "Adenosine as treatment for no-reflow during PPCI could reduce angiographic no-reflow (TIMI flow grade < 3) but was found to increase adverse events." | 2.52 | Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. ( Li, L; Nyi, TS; Su, Q, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scarpone, M | 1 |
| Cenko, E | 1 |
| Manfrini, O | 1 |
| Fu, Q | 1 |
| Lu, W | 1 |
| Huang, YJ | 1 |
| Wu, Q | 1 |
| Wang, LG | 1 |
| Wang, HB | 1 |
| Jiang, SZ | 1 |
| Wang, YJ | 1 |
| Aung Naing, K | 1 |
| Li, L | 3 |
| Su, Q | 3 |
| Wu, T | 1 |
| Liu, Y | 1 |
| Faruk Akturk, I | 1 |
| Arif Yalcin, A | 1 |
| Biyik, I | 1 |
| Sarikamis, C | 1 |
| Turhan Caglar, N | 1 |
| Erturk, M | 1 |
| Celik, O | 1 |
| Uzun, F | 1 |
| Murat Caglar, I | 1 |
| Oner, E | 1 |
| Nyi, TS | 1 |
| Wang, L | 1 |
| Cheng, Z | 1 |
| Gu, Y | 1 |
| Peng, D | 1 |
| Abu Arab, T | 1 |
| Rafik, R | 1 |
| El Etriby, A | 1 |
| Kiernan, TJ | 1 |
| Ruggiero, NJ | 1 |
| Bernal, JM | 1 |
| Don, CW | 1 |
| Witzke, C | 1 |
| Kiernan, GD | 1 |
| Cubeddu, RJ | 1 |
| Yan, BP | 1 |
| Chang, SF | 1 |
| Ma, JY | 1 |
| Qian, JY | 1 |
| Shu, XH | 1 |
| Ge, JB | 1 |
| Niccoli, G | 1 |
| Marino, M | 1 |
| Spaziani, C | 1 |
| Crea, F | 1 |
| Tanzilli, G | 1 |
| Greco, C | 1 |
| Pasceri, V | 1 |
| Pelliccia, F | 1 |
| Arrivi, A | 1 |
| Placanica, A | 1 |
| Mangieri, E | 1 |
| Gilchrist, IC | 1 |
| Wilson, W | 1 |
| Eccleston, D | 1 |
| Sharma, S | 1 |
| Lardizabal, JA | 1 |
| Singh, S | 1 |
| Sandhu, R | 1 |
| Bhambi, BK | 1 |
| Lee, KW | 1 |
| Norell, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Di[NCT05427786] | Phase 4 | 460 participants (Anticipated) | Interventional | 2022-12-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for verapamil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Coronary No-Reflow Phenomenon in Clinical Practice.
Topics: Adenosine; Coronary Vessels; Humans; Microcirculation; Nitroprusside; No-Reflow Phenomenon; Verapami | 2018 |
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
Topics: Adenosine; Cause of Death; Humans; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronar | 2013 |
Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Chi-Square Distribution; Coronary Circulation; Co | 2013 |
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
Topics: Adenosine; Cause of Death; Humans; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronar | 2015 |
Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials.
Topics: Calcium Channel Blockers; Cardiovascular Agents; Diltiazem; Humans; No-Reflow Phenomenon; Randomized | 2015 |
The no-reflow phenomenon in the coronary circulation.
Topics: Adenosine; Animals; Coronary Circulation; Diltiazem; Humans; Nicardipine; Nicorandil; Nitroprusside; | 2009 |
Prevention and treatment of no-reflow.
Topics: Abciximab; Adenosine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Electrocardiography; H | 2010 |
Management of 'no-reflow' complicating reperfusion therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Balloon Occlusion; Coronary Angi | 2008 |
5 trials available for verapamil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction.
Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Follow-Up Studies; Hospital Mortality; Humans; Male; M | 2014 |
Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Vessels; | 2016 |
[Effects of intracoronary administration of nitroglycerin and verapamil for treatment of coronary slow flow phenomenon].
Topics: Adult; Aged; Coronary Circulation; Female; Humans; Male; Middle Aged; Nitroglycerin; No-Reflow Pheno | 2010 |
Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Circul | 2010 |
Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus.
Topics: Abciximab; Administration, Intravenous; Aged; Antibodies, Monoclonal; Coronary Vasospasm; Female; Gr | 2012 |
3 other studies available for verapamil and No-Reflow Phenomenon
| Article | Year |
|---|---|
Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Atropine; Bradycardia; Coronary Angiography; Female; | 2013 |
No-reflow: Still searching for that magic bullet.
Topics: Angioplasty, Balloon, Coronary; Coronary Circulation; Dipyridamole; Humans; Myocardial Infarction; N | 2010 |
How to manage no reflow phenomenon with local drug delivery via a rapid exchange catheter.
Topics: Aged; Angioplasty, Balloon, Coronary; Catheters; Coronary Angiography; Drug Administration Routes; D | 2011 |